Celularity Inc.

NASDAQ:CELU

Biotechnology

Healthcare
$1.83 +138.53%

+$1.22 today

Market cap
$52.97M
Beta
0.54
P/E (TTM)
-0.6
EPS (TTM)
-$3.58
52W Low $0.56High $4.00

Volume 0.00M

Average 0.13M

CELU Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

Celularity Inc.NASDAQ: CELU

Depreciation & Amortization · Q4 FY2025 · quarter ended Dec 2025

Depreciation & amortization declines year over year

Q4 FY2025 depreciation & amortization of $1.8M fell 3.9% year over year, ahead of the -7.9% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 1.2% from the prior quarter. Over 3 fiscal years it compounded at -8.2% a year.

Context

  • Depreciation & amortization amounted to 27.5% of revenue in FY2025, up 12.9 pp from a year earlier.
  • Depreciation & amortization increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -3.9% holds above the trailing-twelve-month pace of -7.9%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterDec 2025
$1.8M-1.2% QoQ
Last fiscal yearDec 2025
$7.3M-7.9% YoY
LTMDec 2025
$7.3M-7.9% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-3.9%——
1 year-7.9%——
3-year CAGR-8.2%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
7.3M USD
Year-over-year change
-7.9%
4-year CAGR
-4.6%

Depreciation & Amortization vs competitors

How CELU compares with its peers on the latest reported figures

  • CELU's LTM Dec 2025 depreciation & amortization of $7.3M is the largest of the 4 companies compared; the peer median is $0.
  • Its year-over-year change of -7.9% is the lowest of 2, against a peer median of +7.1%.
  • Depreciation & amortization amounts to 27.5% of revenue for CELU, versus a peer median of 2.5%.
CELU Competitors Peer median
Depreciation & Amortization for CELU and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CELUCelularity Inc.LTM Dec 2025$7.3M -7.9%-8.2%27.5%
ATNMActinium Pharmaceuticals, Inc.LTM Jun 2026$873K +7.1%+5.5%2.5%
PYPDPolyPid Ltd.LTM Dec 2025$0 ———
ANVSAnnovis Bio, Inc.LTM Mar 2026$0 ———
Peer median (excluding CELU) $0+7.1%+5.5%2.5%

Competitors are the stored peer set for CELU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(100.12M)14.19M(196.3M)(57.89M)(91.72M)
Depreciation & Amortization8.82M9.44M11.48M7.92M7.3M
Deferred Income Tax00003K
Stock-Based Compensation40.01M15.86M15.02M11.57M10.38M
Change in Working Capital(5.71M)(15.45M)(6.77M)22.2M33.59M
Accounts Receivables(1.91M)(3.58M)(6.83M)(3.97M)7.55M
Inventory(6.42M)(16.89M)(865K)6.28M10.25M
Accounts Payables0009.24M3.13M
Other Working Capital2.62M5.02M919K10.65M12.67M
Other Non-Cash Items(53.1M)(161.91M)137.89M9.8M27.19M
Operating Cash Flow(110.1M)(137.88M)(38.69M)(6.4M)(13.25M)
Capital Expenditures(6.2M)(5.24M)(4.05M)(161K)0
Acquisitions (Net)000(1.5M)0
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities300K002.18M0
Investing Cash Flow(5.9M)(5.24M)(4.05M)514K0
Debt Repayment039.2M11.31M7.1M(121K)
Common Stock Issued638K53.37M5.43M58K24.42M
Common Stock Repurchased00000
Dividends Paid0000(5.9M)
Other Financing Activities97.92M27.26M7.35M(459K)255K
Financing Cash Flow98.56M119.84M24.09M6.7M18.65M
Effect of Forex Changes00000
Net Change in Cash(17.44M)(23.27M)(18.64M)814K5.4M
Free Cash Flow(116.3M)(143.11M)(42.73M)(6.56M)(13.25M)

Celularity Inc.

NASDAQ:CELU

Intrinsic Alpha fair value

Locked

Current Price

$1.83

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.